Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2025; 31(48): 113856
Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.113856
Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.113856
AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma
Xue Zhang, Min-Jun Liao, Li-Ying Ren, Shao-Ping She, Ran Fei, Xu Cong, Dong-Bo Chen, Hong-Song Chen, Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing 100044, China
Min-Jun Liao, Yuan-Ping Zhou, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Wan-Ying Qin, Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin 541000, Guangxi Zhuang Autonomous Region, China
Shao-Wei Mu, Department of Hepatobiliary Surgery, Peking University People’s Hospital, Beijing 100044, China
Hong-Song Chen, Peking University Third Hospital, Beijing 100191, China
Co-first authors: Xue Zhang and Min-Jun Liao.
Co-corresponding authors: Dong-Bo Chen and Hong-Song Chen.
Author contributions: Zhang X and Liao MJ contributed to data analysis and manuscript writing; Ren LY, Qin WY, Mu SW, She SP, Fei R and Cong X were responsible for patient enrollment and data collection; Zhou YP provided patient care and study materials; Chen DB and Chen HS conceived and supervised the study; Zhang X and Liao MJ contributed equally to this manuscript and are co-first authors; Chen DB and Chen HS contributed equally to this manuscript and are co-corresponding authors. All authors reviewed and approved the final manuscript.
Supported by National Key Sci-Tech Special Project of China, No. 2018ZX10302207; Beijing Nova Program, No. 20250484965; Beijing Natural Science Foundation, No. 7222191 and No. 7244426; Fundamental Research Funds for the Central Universities, Peking University, No. PKU2024XGK005; Peking University Medicine Seed Fund for Interdisciplinary Research, No. BMU2021MX007 and No. BMU2022MX001; Fundamental Research Funds for the Central Universities, Peking University People’s Hospital Scientific Research Development Funds, No. RDX2020-06 and No. RDJ2022-14; and the Qi-Min Project.
Institutional review board statement: The study protocol, conducted in accordance with the principles of the Declaration of Helsinki, was approved by the Institutional Review Board of each participating center of Peking University People’s Hospital (Approval No. 2024PHB061-001), NanFang Hospital of Southern Medical University (Approval No. NFEC-202305-K32-01), and Affiliated Hospital of Guilin Medical University (Approval No. 2021WJWZC14).
Informed consent statement: Written informed consent was obtained from all participants prior to the initiation of combined therapy.
Conflict-of-interest statement: The authors declare no conflict of interest.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: If reasonably necessary, the datasets used and analyzed in this study can be obtained from the corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Song Chen, Professor, Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China.
Received: September 9, 2025
Revised: October 11, 2025
Accepted: November 10, 2025
Published online: December 28, 2025
Processing time: 110 Days and 2.6 Hours
Revised: October 11, 2025
Accepted: November 10, 2025
Published online: December 28, 2025
Processing time: 110 Days and 2.6 Hours
Core Tip
Core Tip: This multicenter study developed and validated a novel AADN score to predict survival in patients with unre